Shield Therapeutics Stock Price, News & Analysis (LON:STX)

GBX 112.50 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous CloseGBX 112.50
Today's RangeGBX 112 - GBX 112
52-Week RangeGBX 108 - GBX 173
Volume175 shs
Average Volume2,980 shs
Market Capitalization£94.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Shield Therapeutics (LON:STX)

Shield Therapeutics logoShield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Receive STX News and Ratings via Email

Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolLON:STX
CUSIPN/A
Phone+44-191-5118500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares116,430,000

Shield Therapeutics (LON:STX) Frequently Asked Questions

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

Where is Shield Therapeutics' stock going? Where will Shield Therapeutics' stock price be in 2017?

4 analysts have issued twelve-month target prices for Shield Therapeutics' stock. Their forecasts range from GBX 220 to GBX 265. On average, they anticipate Shield Therapeutics' share price to reach GBX 242.75 in the next year. View Analyst Ratings for Shield Therapeutics.

Who are some of Shield Therapeutics' key competitors?

Who are Shield Therapeutics' key executives?

Shield Therapeutics' management team includes the folowing people:

  • Carl Andrew Sterritt, Chief Executive Officer, Director
  • Karl David Keegan Ph.D., Interim Chief Financial Officer (Age 50)
  • Jacqueline Mitchell, Vice President - Regulatory Affairs
  • Paul Steckler, Vice President - Commercial Operations
  • Angela Hildreth, Group Financial Controller and Head of Human Resources
  • David Childs, Manufacturing Director
  • Ashok Dhanrajgir, Non-Executive Director
  • Lynn Drummond, Non-Executive Director (Age 55)

How do I buy Shield Therapeutics stock?

Shares of Shield Therapeutics and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shield Therapeutics' stock price today?

One share of Shield Therapeutics stock can currently be purchased for approximately GBX 112.50.

How big of a company is Shield Therapeutics?

Shield Therapeutics has a market capitalization of £94.64 million.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.


MarketBeat Community Rating for Shield Therapeutics (STX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shield Therapeutics (LON:STX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 242.75GBX 242.75GBX 244GBX 243

Shield Therapeutics (LON:STX) Consensus Price Target History

Price Target History for Shield Therapeutics (LON:STX)

Shield Therapeutics (LON:STX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/21/2017FinnCapReiterated RatingBuyGBX 265View Rating Details
11/8/2017Peel HuntReiterated RatingBuyGBX 220View Rating Details
10/10/2017Liberum CapitalReiterated RatingBuyGBX 245View Rating Details
1/6/2017Canaccord GenuityReiterated RatingBuyGBX 241View Rating Details
(Data available from 12/16/2015 forward)

Earnings

Earnings History for Shield Therapeutics (LON:STX)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Shield Therapeutics (LON:STX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Shield Therapeutics (LON:STX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Shield Therapeutics (LON STX)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Shield Therapeutics (LON STX) News Headlines

Source:
DateHeadline
Shield Therapeutics plcs (STX) "Buy" Rating Reaffirmed at FinnCapShield Therapeutics plc's (STX) "Buy" Rating Reaffirmed at FinnCap
www.americanbankingnews.com - November 23 at 11:20 PM
Shield Therapeutics Plc :STX-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 22, 2017Shield Therapeutics Plc :STX-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 22, 2017
finance.yahoo.com - November 22 at 8:54 AM
Shield Therapeutics Plc breached its 50 day moving average in a Bearish Manner : STX-GB : November 15, 2017Shield Therapeutics Plc breached its 50 day moving average in a Bearish Manner : STX-GB : November 15, 2017
finance.yahoo.com - November 15 at 12:29 PM
Shield Therapeutics Completes Feraccru Trial EnrollmentShield Therapeutics Completes Feraccru Trial Enrollment
www.morningstar.co.uk - October 11 at 8:32 PM
Shield Therapeutics plc ("Shield" or the "Group") Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study - GlobeNewswire (press release)Shield Therapeutics plc ("Shield" or the "Group") Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study - GlobeNewswire (press release)
globenewswire.com - October 11 at 3:32 PM
Shield Therapeutics plc ("Shield" or the "Group") Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 studyShield Therapeutics plc ("Shield" or the "Group") Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study
finance.yahoo.com - October 10 at 7:12 AM
Shield Therapeutics PLC (STX) Given Buy Rating at Peel HuntShield Therapeutics PLC (STX) Given Buy Rating at Peel Hunt
www.americanbankingnews.com - September 24 at 9:40 AM
Shield Therapeutics PLCs (STX) "Buy" Rating Reaffirmed at Liberum CapitalShield Therapeutics PLC's (STX) "Buy" Rating Reaffirmed at Liberum Capital
www.americanbankingnews.com - September 24 at 9:40 AM
Shield Therapeutics PLC (STX) PT Lowered to GBX 265Shield Therapeutics PLC (STX) PT Lowered to GBX 265
www.americanbankingnews.com - September 23 at 12:16 AM
Why Id ditch this high-risk growth share to buy British American Tobacco plc - Motley Fool UKWhy I'd ditch this high-risk growth share to buy British American Tobacco plc - Motley Fool UK
www.fool.co.uk - September 20 at 9:34 AM
Why Id ditch this high-risk growth share to buy British American Tobacco plc - Motley Fool UKWhy I'd ditch this high-risk growth share to buy British American Tobacco plc - Motley Fool UK
www.fool.co.uk - September 20 at 9:34 AM
Shield Therapeutics PLC (STX) Earns Buy Rating from Liberum CapitalShield Therapeutics PLC (STX) Earns Buy Rating from Liberum Capital
www.americanbankingnews.com - September 17 at 10:26 AM
FinnCap Reaffirms Buy Rating for Shield Therapeutics PLC (STX)FinnCap Reaffirms Buy Rating for Shield Therapeutics PLC (STX)
www.americanbankingnews.com - September 17 at 12:58 AM
Shield Therapeutics PLC (STX) Now Covered by FinnCapShield Therapeutics PLC (STX) Now Covered by FinnCap
www.americanbankingnews.com - September 10 at 2:40 PM
Shield Therapeutics plc ("Shield" or the "Group") US Composition of Matter PatentShield Therapeutics plc ("Shield" or the "Group") US Composition of Matter Patent
finance.yahoo.com - September 6 at 8:44 AM
Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017
finance.yahoo.com - August 31 at 10:38 AM
Shield Therapeutics PLCs (STX) "Buy" Rating Reiterated at Peel HuntShield Therapeutics PLC's (STX) "Buy" Rating Reiterated at Peel Hunt
www.americanbankingnews.com - July 9 at 1:06 PM
Biomarker data on ferric maltol in patients - London South East (registration) (blog)Biomarker data on ferric maltol in patients - London South East (registration) (blog)
www.lse.co.uk - June 22 at 6:51 PM
Is Shield Therapeutics plc a better bet than AstraZeneca plc?Is Shield Therapeutics plc a better bet than AstraZeneca plc?
uk.finance.yahoo.com - September 20 at 10:33 AM
Shield Therapeutics plc: Composition of Matter Patent Granted on Feraccru(R)Shield Therapeutics plc: Composition of Matter Patent Granted on Feraccru(R)
globenewswire.com - September 8 at 11:23 AM

SEC Filings

Shield Therapeutics (LON:STX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Shield Therapeutics (LON STX) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.